Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
Tang MW, Van der Tuin D, Aydin M, Heijmans J, Van de Loosdrecht AA, Meijer E, Rutten CE, Wondergem M, Janssen JJWM, Donker ML, Hazenberg MD, Zweegman S, Biemond BJ, De Leeuw DC, Nur E. Tang MW, et al. Among authors: zweegman s. Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14370. Online ahead of print. Eur J Haematol. 2024. PMID: 39726233
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.
Korst CLBM, Groen K, Bosman PWC, van der Valk F, Verkleij CPM, Kruyswijk S, de Ruijter MEM, Heijink DM, Kuipers MT, Zweegman S, van de Donk NWCJ. Korst CLBM, et al. Among authors: zweegman s. Hemasphere. 2024 Jul 24;8(7):e132. doi: 10.1002/hem3.132. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39050549 Free PMC article. No abstract available.
Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study.
van Kwawegen CB, Atiq F, Endenburg D, Fijnvandraat K, van Galen KPM, Cnossen MH, Schols SEM, Kruip MJHA, van Heerde WL, de Meris J, van der Bom JG, Eikenboom J, Meijer K, Leebeek FWG; WiN study group. van Kwawegen CB, et al. J Thromb Haemost. 2024 Dec;22(12):3460-3472. doi: 10.1016/j.jtha.2024.08.028. Epub 2024 Sep 28. J Thromb Haemost. 2024. PMID: 39343102 Free article.
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, de Waal EGM, Westerman M, Velders GA, de Heer K, Leys RBL, van Kampen RJW, Stege CAM, Seefat MR, Nijhof IS, van der Spek E, Klein SK, van de Donk NWCJ, Ypma PF, Zweegman S. Groen K, et al. Among authors: zweegman s. Hemasphere. 2024 Jul 4;8(7):e85. doi: 10.1002/hem3.85. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38966208 Free PMC article. No abstract available.
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.
Bruins WSC, Rentenaar R, Newcomb J, Zheng W, Ruiter RWJ, Baardemans T, Poma E, Moore C, Robinson GL, Lublinsky A, Zhang Y, Syed S, Milhollen M, Dash AB, van de Donk NWCJ, Groen RWJ, Zweegman S, Mutis T. Bruins WSC, et al. Among authors: zweegman s. Hemasphere. 2024 Nov 14;8(11):e70039. doi: 10.1002/hem3.70039. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39544624 Free PMC article.
Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.
De Wee EM, Klaij K, Eikenboom HC, Van Der Bom JG, Fijnvandraat K, Laros-Van Gorkom BA, Mauser-Bunschoten EP, Meijer K, Goverde G, Van Der Linden PW, Rijken DC, Leebeek FW; WiN Study Group. De Wee EM, et al. Haemophilia. 2012 May;18(3):444-51. doi: 10.1111/j.1365-2516.2011.02645.x. Epub 2011 Sep 12. Haemophilia. 2012. PMID: 21910790
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.
Smits F, Groen K, Levin MD, Stege C, van Kampen RJW, van der Spek E, Bilgin YM, Thielen N, Nijhof IS, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, Heer K, Vekemans MM, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S. Smits F, et al. Among authors: zweegman s. Blood. 2024 Nov 22:blood.2024025868. doi: 10.1182/blood.2024025868. Online ahead of print. Blood. 2024. PMID: 39576961
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.
Mai EK, Nogai A, Lokhorst HM, van der Holt B, Zweegman S, Weisel KC, Croockewit S, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Bos GMJ, Brossart P, Ypma P, Hanoun C, Bertsch U, Hielscher T, Salwender HJ, Scheid C, Goldschmidt H, Sonneveld P. Mai EK, et al. Among authors: zweegman s. Hemasphere. 2024 Nov 20;8(11):e70052. doi: 10.1002/hem3.70052. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39569355 Free PMC article. No abstract available.
353 results